Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Fineline Cube Jan 14, 2026
Company Deals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

Fineline Cube Jan 14, 2026
Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Company Deals

Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Fineline Cube Jan 14, 2026
Company Deals

Tencent Invests USD 30 Million in Early Cancer Detection Firm Insighta, Backed by Prenetics

Fineline Cube Oct 18, 2024

Prenetics Global Limited (NASDAQ: PRE), a prominent health sciences company with operations in the US...

Company Deals

LaNova Medicines Secures RMB 300 Million in Series C1 Financing to Advance Cancer Therapy Pipeline

Fineline Cube Oct 18, 2024

LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the successful completion of...

Company

Abbott Laboratories Posts 9.4% Q3 Sales Growth, Driven by Medical Devices and Pharmaceuticals

Fineline Cube Oct 18, 2024

Abbott Laboratories (NYSE: ABT), a U.S.-based healthcare giant, has reported its financial results for the...

Company Deals

Chengdu Baiyu Pharmaceutical Strikes Licensing Deal with Novartis for Unannounced Anti-Tumor Asset

Fineline Cube Oct 18, 2024

Chengdu Baiyu Pharmaceutical Co., Ltd., a Chinese pharmaceutical company, has entered into a licensing agreement...

Company Deals

Cryofocus Medtech Partners with Guangzhou Medical University Hospital for Cryoballoon Ablation R&D

Fineline Cube Oct 17, 2024

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based leader in cryoablation treatment, and the...

Company Drug

Kintor Pharmaceutical Initiates Phase II/III Trial for KX-826 Tincture 1.0% in Treating Male Androgenetic Alopecia

Fineline Cube Oct 17, 2024

Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the commencement...

Company Medical Device

Novocure’s Optune Lua Wins FDA Approval for mNSCLC Treatment in Combination with Immunotherapies

Fineline Cube Oct 17, 2024

Novocure (NASDAQ: NVCR), a Swiss firm renowned for its pioneering Tumor Treating Fields (TTFields) cancer...

Company Deals

Servier and HUST Forge Partnership to Cultivate Innovative Therapies through SHINEDocs Program

Fineline Cube Oct 17, 2024

French pharmaceutical company Servier has joined forces with Huazhong University of Science and Technology (HUST),...

Company Drug

Innovent Biologics’ Picankibart Achieves Positive Results in Phase II UC Study

Fineline Cube Oct 17, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company

Bayer AG Launches China Innovation Hub to Boost Local R&D and Global Integration

Fineline Cube Oct 17, 2024

Bayer AG (ETR: BAYN), a German multinational pharmaceutical and life sciences giant, has announced the...

Company Deals

Lexicon Pharmaceuticals Strikes Licensing Deal with Viatris for Global Expansion of Sotagliflozin

Fineline Cube Oct 17, 2024

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has entered into a licensing agreement with Viatris Inc. (NASDAQ:...

Company Drug

Johnson & Johnson’s Nipocalimab Shows Promise in Treating Adolescent Myasthenia Gravis in Phase II/III Trial

Fineline Cube Oct 17, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a US pharmaceutical giant, has reported encouraging outcomes from...

Policy / Regulatory

NHSA Standardizes NRDL Drug Purchases to Combat Prescription Fraud

Fineline Cube Oct 17, 2024

The National Healthcare Security Administration (NHSA) has issued a notification aimed at standardizing the management...

Policy / Regulatory

Shanxi Province Announces Historic Drug Procurement Batch with 81 Products for 2024

Fineline Cube Oct 17, 2024

On October 16, 2024, Shanxi Province’s drug procurement platform announced a notice regarding the submission...

Company Drug

Alphamab Oncology and CSPC Pharma’s KN026 Phase III Trial for Breast Cancer Gets NMPA Approval

Fineline Cube Oct 17, 2024

Alphamab Oncology (HKG: 9966) and CSPC Pharma (HKG: 1093) have jointly announced that their Phase...

Company Deals

Boehringer Ingelheim Pledges USD 5 Million to WHO Foundation for Global Healthcare Advancement

Fineline Cube Oct 16, 2024

Boehringer Ingelheim (BI), a leading German pharmaceutical company, has joined forces with the World Health...

Company

J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress

Fineline Cube Oct 16, 2024

Johnson & Johnson (J&J, NYSE: JNJ) has released its financial report for the third quarter...

Company Drug

Shanghai Junshi Biosciences’ Toripalimab Wins Marketing Approvals in India and Hong Kong for Nasopharyngeal Carcinoma

Fineline Cube Oct 16, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biotech company based in...

Company

Eli Lilly Launches Medical Innovation Center and Gateway Labs in Beijing to Accelerate Clinical Trials and R&D

Fineline Cube Oct 16, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical corporation in the US, has announced...

Company Drug

Jiangsu Hengrui Resubmits Application for Camrelizumab Combo in HCC to FDA

Fineline Cube Oct 16, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company based in China, has...

Posts pagination

1 … 226 227 228 … 609

Recent updates

  • AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D
  • Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
  • WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments
  • Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases
  • ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Company

WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments

Company Deals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.